What is the Origin of Adult GHD Treatment?

The concept stems from the recognition of GHD as a distinct clinical entity in adults, often resulting from pituitary or hypothalamic disease or trauma. Recombinant DNA technology in the late 20th century made rhGH replacement therapy a viable clinical option. Endocrinological practice established specific diagnostic criteria, such as the insulin tolerance test (ITT), to accurately confirm the diagnosis in the adult population.

What is the Mechanism of Adult GHD Treatment?

Recombinant human growth hormone, administered subcutaneously, binds to GH receptors on target cells, including hepatocytes and adipocytes. This binding stimulates the hepatic production of Insulin-like Growth Factor 1 (IGF-1), which is the primary mediator of many GH actions throughout the body. The therapeutic mechanism involves restoring the somatotropic axis, leading to improved lipid profiles, increased lean body mass, and enhanced cardiac function. Careful titration of the rhGH dose is crucial to maintain IGF-1 levels within the age-appropriate reference range and minimize potential side effects.

Adult GHD Treatment

Meaning

Clinical intervention for Growth Hormone Deficiency (GHD) in individuals who have completed skeletal maturation, often characterized by altered body composition and reduced bone mineral density. This condition is distinct from childhood GHD, presenting with a constellation of metabolic and psychological symptoms. Treatment involves the precise administration of recombinant human growth hormone (rhGH) to restore physiological hormone levels. The primary goal is to mitigate long-term cardiovascular and psychological sequelae associated with this specific adult endocrine disorder.